Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial

Approximately 25% of patients with early-stage breast cancer who receive (neo)adjuvant chemotherapy experience a recurrence within 5 years. Improvements in therapy are greatly needed. To determine if pembrolizumab plus neoadjuvant chemotherapy (NACT) in early-stage breast cancer is likely to be succ...

Full description

Bibliographic Details

Published in:	JAMA oncology Vol. 6; no. 5; p. 676
Main Authors:	Nanda, Rita, Liu, Minetta C, Yau, Christina, Shatsky, Rebecca, Pusztai, Lajos, Wallace, Anne, Chien, A Jo, Forero-Torres, Andres, Ellis, Erin, Han, Heather, Clark, Amy, Albain, Kathy, Boughey, Judy C, Jaskowiak, Nora T, Elias, Anthony, Isaacs, Claudine, Kemmer, Kathleen, Helsten, Teresa, Majure, Melanie, Stringer-Reasor, Erica, Parker, Catherine, Lee, Marie C, Haddad, Tufia, Cohen, Ronald N, Asare, Smita, Wilson, Amy, Hirst, Gillian L, Singhrao, Ruby, Steeg, Katherine, Asare, Adam, Matthews, Jeffrey B, Berry, Scott, Sanil, Ashish, Schwab, Richard, Symmans, W Fraser, van 't Veer, Laura, Yee, Douglas, DeMichele, Angela, Hylton, Nola M, Melisko, Michelle, Perlmutter, Jane, Rugo, Hope S, Berry, Donald A, Esserman, Laura J
Format:	Journal Article
Language:	English
Published:	United States 01.05.2020
Subjects:	Antibodies, Monoclonal, Humanized - pharmacology Antibodies, Monoclonal, Humanized - therapeutic use Breast Neoplasms - drug therapy Breast Neoplasms - pathology Female Humans Neoadjuvant Therapy - methods Neoplasm Staging Programmed Cell Death 1 Receptor - therapeutic use
ISSN:	2374-2445, 2374-2445
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!